Aktienanalyse zu AC Immune AG (ACIU)ACIUAC Immune AG

AC Immune SA is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on precision medicine for neurodegenerative diseases. It designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The Company's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. It has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology. It operates in the Healthcare sector.

AC Immune SA may not be a good buy right now, as it has a current price of $2.50 and an RSI of 34.89, indicating it is oversold. The company recently reported a net income of $2.4 million in Q2, a significant recovery from losses, but the overall trend shows a 25.60% decline year-to-date. The main risk is the high forward P/E ratio of 16.64, suggesting the stock may be overvalued relative to its earnings potential.

3 analysts cover ACIU: 3 rate it Buy, 0 Hold and 0 Sell. The average price target is 12.00.